These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10620637)

  • 1. More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
    Rebbeck TR
    J Natl Cancer Inst; 2000 Jan; 92(1):76. PubMed ID: 10620637
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
    Ando Y; Tateishi T; Sekido Y; Yamamoto T; Satoh T; Hasegawa Y; Kobayashi S; Katsumata Y; Shimokata K; Saito H
    J Natl Cancer Inst; 1999 Sep; 91(18):1587-90. PubMed ID: 10491442
    [No Abstract]   [Full Text] [Related]  

  • 3. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online.
    Walker AH; Jaffe JM; Gunasegaram S; Cummings SA; Huang CS; Chern HD; Olopade OI; Weber BL; Rebbeck TR
    Hum Mutat; 1998; 12(4):289. PubMed ID: 10660343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients.
    Paris PL; Kupelian PA; Hall JM; Williams TL; Levin H; Klein EA; Casey G; Witte JS
    Cancer Epidemiol Biomarkers Prev; 1999 Oct; 8(10):901-5. PubMed ID: 10548319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
    Wojnowski L; Hustert E; Klein K; Goldammer M; Haberl M; Kirchheiner J; Koch I; Klattig J; Zanger U; Brockmöller J
    J Natl Cancer Inst; 2002 Apr; 94(8):630-1; author reply 631-2. PubMed ID: 11959896
    [No Abstract]   [Full Text] [Related]  

  • 6. CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations.
    Tayeb MT; Clark C; Ameyaw MM; Haites NE; Evans DA; Tariq M; Mobarek A; Ofori-Adjei D; McLeod HL
    Pharmacogenetics; 2000 Nov; 10(8):753-6. PubMed ID: 11186137
    [No Abstract]   [Full Text] [Related]  

  • 7. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity.
    Sata F; Sapone A; Elizondo G; Stocker P; Miller VP; Zheng W; Raunio H; Crespi CL; Gonzalez FJ
    Clin Pharmacol Ther; 2000 Jan; 67(1):48-56. PubMed ID: 10668853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification?
    Kittles RA; Chen W; Panguluri RK; Ahaghotu C; Jackson A; Adebamowo CA; Griffin R; Williams T; Ukoli F; Adams-Campbell L; Kwagyan J; Isaacs W; Freeman V; Dunston GM
    Hum Genet; 2002 Jun; 110(6):553-60. PubMed ID: 12107441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
    Rebbeck TR; Jaffe JM; Walker AH; Wein AJ; Malkowicz SB
    J Natl Cancer Inst; 1998 Aug; 90(16):1225-9. PubMed ID: 9719084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4.
    Ball SE; Scatina J; Kao J; Ferron GM; Fruncillo R; Mayer P; Weinryb I; Guida M; Hopkins PJ; Warner N; Hall J
    Clin Pharmacol Ther; 1999 Sep; 66(3):288-94. PubMed ID: 10511065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men.
    Bangsi D; Zhou J; Sun Y; Patel NP; Darga LL; Heilbrun LK; Powell IJ; Severson RK; Everson RB
    Urol Oncol; 2006; 24(1):21-7. PubMed ID: 16414488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians.
    van Schaik RH; de Wildt SN; van Iperen NM; Uitterlinden AG; van den Anker JN; Lindemans J
    Clin Chem; 2000 Nov; 46(11):1834-6. PubMed ID: 11067821
    [No Abstract]   [Full Text] [Related]  

  • 13. Direct evidence for the higher frequency of CYP2C19 allelic heterozygotes in Chinese subjects than in white subjects.
    Xie HG
    Clin Pharmacol Ther; 1997 Dec; 62(6):691-2. PubMed ID: 9433397
    [No Abstract]   [Full Text] [Related]  

  • 14. [Cytochrome P450 2C19 gene polymorphism in four Chinese nationality populations].
    Zhang S; Dong Z; Tang L; Zhou Q; Wu Z
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Feb; 19(1):52-4. PubMed ID: 11836688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia.
    Tayeb MT; Clark C; Sharp L; Haites NE; Rooney PH; Murray GI; Payne SN; McLeod HL
    Oncol Rep; 2002; 9(3):653-5. PubMed ID: 11956645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4.
    Hustert E; Zibat A; Presecan-Siedel E; Eiselt R; Mueller R; Fuss C; Brehm I; Brinkmann U; Eichelbaum M; Wojnowski L; Burk O
    Drug Metab Dispos; 2001 Nov; 29(11):1454-9. PubMed ID: 11602521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4.
    Zeigler-Johnson CM; Walker AH; Mancke B; Spangler E; Jalloh M; McBride S; Deitz A; Malkowicz SB; Ofori-Adjei D; Gueye SM; Rebbeck TR
    Hum Hered; 2002; 54(1):13-21. PubMed ID: 12446983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations.
    Schirmer M; Toliat MR; Haberl M; Suk A; Kamdem LK; Klein K; Brockmöller J; Nürnberg P; Zanger UM; Wojnowski L
    Pharmacogenet Genomics; 2006 Jan; 16(1):59-71. PubMed ID: 16344723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics and ethnoracial differences in smoking.
    Sellers EM
    JAMA; 1998 Jul; 280(2):179-80. PubMed ID: 9669793
    [No Abstract]   [Full Text] [Related]  

  • 20. Two single-tube tetra-primer assays to detect the CYP2C19*2 and *3 alleles of S-mephenytoin hydroxylase.
    Hersberger M; Marti-Jaun J; Rentsch K; Hänseler E
    Clin Chem; 2001 Apr; 47(4):772-4. PubMed ID: 11274039
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.